Jackson Walker partner Leisa Talbert Peschel was featured in a recent Bloomberg Law article examining why hospitals often turn to biotechnology companies as partners to commercialize healthcare innovations and enforce the patent rights behind them.

Leisa explained that university hospitals, especially public institutions, face particular obstacles when they try to bring patent disputes on their own. These include funding restrictions, the high cost of litigation, and sovereign-immunity considerations that can make going it alone impractical.

Partnering with a biotech company can help close that gap. Biotech partners can bring the capital, personnel, commercialization experience, and market presence needed to protect and monetize healthcare inventions. The article notes that these collaborations can be especially valuable before the U.S. International Trade Commission (ITC), where patent owners may seek exclusion orders to block imports of allegedly infringing products.

To read the full article, view “Hospitals Find Biotech Makes a Critical Partner in IP Litigation.”

Meet Leisa

Leisa Talbert Peschel is an intellectual property trial lawyer and counselor who has litigated more than seventy patent infringement cases and led many inter partes reviews and reexaminations. She uses her scientific background to master complex technologies, from streaming and encryption to biotechnology and oil field equipment. Her transactional practice covers IP licensing, trademark and brand management, patent prosecution and portfolio management, due diligence for acquisitions, and patent opinions of counsel. She also writes and speaks often on IP law.